Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.

Abstract

OBJECTIVES Nasal vaccination is an effective regimen to prevent upper respiratory infections. An appropriate adjuvant is required for the development of a nasal vaccine. The safety and efficacy of CpG oligodeoxynucleotide (ODN) as a mucosal adjuvant was examined. METHODS Mice were nasally administered various doses of CpG ODN weekly, a total of three… (More)

Topics

Cite this paper

@article{Kodama2006SafetyAE, title={Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.}, author={Satoru Kodama and Nobuyuki Abe and Takashi Hirano and Masashi Suzuki}, journal={The Laryngoscope}, year={2006}, volume={116 2}, pages={331-5} }